These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 30539796)

  • 1. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms Controlling PD-L1 Expression in Cancer.
    Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
    Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
    Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
    JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
    Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
    Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.